The accumulation of various 25-hydroxylated C 27 -bile alcohols in blood and their excretion in urine are characteristic features of cerebrotendinous xanthomatosis (CTX) which is a recessively inherited inborn error of bile acid synthesis caused by mutations in the mitochondrial sterol 27-hydroxylase (CYP27) gene. These bile alcohols may be intermediates in the alternative cholic acid side chain cleavage pathway from 5β-cholestane-3α,7α,12α-triol, although all enzymes involved in the pathway have not been ascertained. The present study was undertaken to identify enzymes and reactions responsible for the formation of these bile alcohols and to explain the reason why
INTRODUCTION
In the classic bile acid biosynthetic pathway, a series of ring modifications precede side chain cleavage to yield 5β-cholestane-3α,7α-diol and 5β-cholestane-3α,7α,12α-triol.
The side chain of the diol is hydroxylated by mitochondrial sterol 27-hydroxylase show typical CTX-related pathological or biochemical abnormalities (16) . Recently we measured hepatic concentrations of intermediates in bile acid biosynthesis in Cyp27 -/-mice and compared them with those in CTX (17) .
In Cyp27 -/-mice, microsomal concentrations of early intermediates in the bile acid biosynthetic pathway (7α-hydroxycholesterol, 7α-hydroxy-4-cholesten-3-one, 7α,12α-dihydroxy-4-cholesten-3-one, and 5β-cholestane-3α,7α,12α-triol), and 25-hydroxylated bile alcohols (5β-cholestane-3α,7α,12α,25-tetrol, 5β-cholestane-3α,7α,12α,23R,25-pentol, and 5β-cholestane-3α,7α,12α,24R,25-pentol) were all significantly elevated compared with those in Cyp27 +/+ mice, but the levels were much lower than those in CTX patients. Therefore, we speculated that these intermediates were more efficiently metabolized by the 7 potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA in a total volume of 0.3 ml. The reaction was stopped by adding 0.3 ml of methanol and 3 ml of petroleum ether. Formed 7α-hydroxy-4-cholesten-3-one was extracted and quantified by HPLC (31).
Assay of 7 -hydroxy-4-cholesten-3-one 12 -hydroxylase activity-
The activity of 12α-hydroxylase was assayed as described by Noshiro et al. (32) with minor modifications.
Microsomes were incubated for 10 min at 37°C with 7α-hydroxy-4-cholesten-3-one (6 µg dissolved in 5 µl of isopropanol), NADPH (1 mM), and 100 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA in a total volume of 0.3 ml. The incubation was stopped by addition of 5 ml of benzene. Formed 7α,12α-dihydroxy-4-cholesten-3-one was quantified by HPLC (32).
Assay of 5 -cholestane-3 ,7 ,12 -triol 25-hydroxylase activity-Microsomal 5β-
cholestane-3α,7α,12α-triol 25-hydroxylase activity was measured by our method described previously (19) . Microsomes were incubated for 20 min at 37°C with 5β-cholestane-3α,7α,12α-triol (25 nmol dissolved in 10 µl of acetone), NADPH (1.2 mM), glucose-6-phosphate (3.6 mM), 2 units of glucose-6-phosphate dehydrogenase, and 100 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA in a total volume of 0.5 ml. The reaction was stopped by adding 2 ml of ethyl acetate. After addition of 1 µg of 5β-cholestane-3α,7α,12α,27-tetrol as an internal recovery standard, tetrols were extracted twice with 2 ml of ethyl acetate, purified by a Bond Elut SI cartridge, derivatized to TMS ether and quantified by high-resolution GC-MS with SIM.
Assays of 5 -cholestane-3 ,7 ,12 -triol 26-and 27-hydroxylase activities-
The activities of microsomal 5β-cholestane-3α,7α,12α-triol 26-hydroxylase and mitochondrial 5β-cholestane-3α,7α,12α-triol 27-hydroxylase were determined by previously described methods (19) . The microsomes (for 26-hydroxylase) or mitochondria (for 27-hydroxylase) were incubated for 20 min at 37°C with 5β-cholestane-3α,7α,12α-triol (50 nmol dissolved in 12 µl of a 33% aqueous solution of β-cyclodextrin), NADPH (1.2 mM), isocitrate (5 mM) and 0.2 unit of isocitrate dehydrogenase, and 100 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA in a total volume of 0.5 ml. The reaction was stopped with 2 ml of ethyl acetate. After addition of 1 µg of 5β-cholestane-3α,7α,12α,25-tetrol as an internal recovery standard, 5β-cholestane-tetrols were extracted twice with 2 ml of ethyl acetate, purified by a Bond Elut SI cartridge, derivatized to TMS ether and quantified by high-resolution GC-MS with SIM.
Assay of 5 -cholestane-3 ,7 ,12 ,25-tetrol 23R, 24R, 24S and 27-hydroxylase activities-As reported previously (19) , microsomes were incubated for 20 min at 37°C with 5β-cholestane-3α,7α,12α,25-tetrol (100 nmol dissolved in 10 µl of 0.75% (w/v) Tween-80 solution), NADPH (1.2 mM), glucose-6-phosphate (3.6 mM), 2 units of glucose-6-phosphate dehydrogenase, and 100 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA in a total volume of 0.5 ml. The reaction was stopped by adding 2 ml of ethyl acetate. After addition of 1 µg of 5β-cholestane-3α,7α,12α,27-tetrol as an internal recovery standard, bile alcohols were extracted twice with 2 ml of ethyl acetate, purified by a Bond Elut SI cartridge, derivatized to TMS ether and quantified by high-resolution
GC-MS with SIM.
Assay of testosterone 6 -hydroxylase activity-The activity of testosterone 6β-hydroxylase was measured according to the method described by Hayashi et al. (33) with minor modifications. Microsomes were incubated for 30 min at 37°C with testosterone (300 nmol dissolved in 5 µl of methanol), NADPH (1.2 mM), glucose-6-phosphate (3.6 mM), 2 units of glucose-6-phosphate dehydrogenase, and 100 mM potassium phosphate buffer (pH 7.4) containing 0.1 mM EDTA in a total volume of 0.5 ml. The incubation was stopped by addition of 3 ml of benzene. Formed 6β-hydroxytestosterone was quantified by HPLC (33). Table I shows hepatic mitochondrial 27-hydroxylase activities toward cholesterol and 5β-cholestane-3α,7α,12α-triol. The activities of 27-hydroxylation of both cholesterol and 5β-cholestane-3α,7α,12α-triol were virtually absent in Cyp27 -/-mice while very low but significant activities were detected in the CTX patient.
Statistics-Data

RESULTS
The activities of enzymes involved in cholic acid biosynthesis from cholesterol via 25-hydroxylation side chain cleavage pathway are summarized in Fig. 2 . Cholesterol 7α-hydroxylase (CYP7A1) activities were up-regulated in both CTX patient and Cyp27
-/-mice compared with the controls. In contrast, microsomal 5β-cholestane-3α,7α,12α-triol 25-hydroxylase and 5β-cholestane-3α,7α,12α,25-tetrol 24S-hydroxylase activities
were not stimulated in the CTX patient, whereas both enzyme activities in Cyp27 -/-mice were markedly up-regulated 5.5-fold and 7.5-fold, respectively, compared with those in Cholesterol 7α-hydroxylase activity was elevated 6.5-fold in male Cyp27 -/-mice while the elevation was only 2-fold in female Cyp27 -/-mice. In contrast, up-regulation of 25-hydroxylase in female Cyp27 -/-mice (5.5-fold) was similar to that in male Cyp27 -/-mice (5.3-fold).
Activities of side chain hydroxylations of 5β-cholestane-3α,7α,12α-triol and 5β-cholestane-3α,7α,12α,25-tetrol in CTX patient and control humans are shown in Table II .
Significant activities for the 26-hydroxylation of 5β-cholestane-3α,7α,12α-triol and 23R-, 24R-, and 27-hydroxylations of 5β-cholestane-3α,7α,12α,25-tetrol were detected in microsomes from the CTX patient, but these activities were within the 95% confidence intervals for control mean activities. Correlations between the activity of microsomal testosterone 6β-hydroxylase (CYP3A) and other hydroxylase activities from eight control human subjects are summarized in Table IV . Microsomal activities of 5β-cholestane-3α,7α,12α-triol 26-hydroxylase and 5β-cholestane-3α,7α,12α,25-tetrol 23R-, 24R-, 24S-, and 27-hydroxylases were all significantly correlated with testosterone 6β-hydroxylase activity. However, microsomal cholesterol 7α-hydroxylase, 12α-hydroxylase and mitochondrial 5β-cholestane-3α,7α,12α-triol 27-hydroxylase activities were not correlated with testosterone 6β-hydroxylase activity.
Recombinant overexpressed human CYP3A4 (9.2 pmol P450) was incubated at 37°C for 5 hours with 50 µM of 5β-cholestane-3α,7α,12α-triol, and the bile alcohol fraction was derivatized with TMS and analyzed by GC-MS. Figure 5A represents the total ion chromatogram of the sample. Mass spectrometric analysis confirmed the formations of 5β-cholestane-3α,7α,12α,25-tetrol (III), 5β-cholestane-3α,7α,12α,26-tetrol (IV), 5β-cholestane-3α,7α,12α,23R,25-pentol (V), 5β-cholestane-3α,7α,12α,24R,25-pentol (VI) and 5β-cholestane-3α,7α,12α,24S,25-pentol (VII). Reference compounds for 5β-cholestane-3α,7α,12α,23ξ-tetrol (I) and 5β-cholestane-3α,7α,12α,24ξ-tetrol (II) were not available, but they were identified from previous GC-MS data (34). In addition, several unknown 25-, 26-or 27-hydroxylated bile alcohol peaks (a-e) were detected in the incubation mixture. These bile alcohol peaks were not observed when boiled (for 5 min) CYP3A4
was used for the assay (Fig. 5B) . The activities of 25-and 26-hydroxylations of 5β-cholestane-3α,7α,12α-triol and 23R-, 24R-, 24S-and 27-hydroxylations of 5β-cholestane-3α,7α,12α,25-tetrol by the recombinant CYP3A4 were 4894, 318, 1820, 166, 245 and 46 pmol/min/nmol P450, respectively. The ratio of these six hydroxylation activities in CYP3A4 was similar to that in human liver microsomes and a strong correlation (r = 0.939, P<0.01, n = 6) existed between the six enzyme activities by CYP3A4 and those in human liver microsomes (mean activities from ten control humans).
IC 50 values for troleandomycin, a specific inhibitor of CYP3A, determined by using recombinant human CYP3A4 and pooled human liver microsomes were shown in Table   V . Troleandomycin markedly inhibited 6β-hydroxylation of testosterone, 25-and 26-hydroxylations of 5β-cholestane-3α,7α,12α-triol and 23R-, 24R-, 24S-and 27-hydroxylations of 5β-cholestane-3α,7α,12α,25-tetrol in both recombinant CYP3A4 and microsomes, but IC 50 values for microsomes were somewhat higher than those for recombinant CYP3A4. 
DISCUSSION
Our previous studies showed that several side chain hydroxylations of 5β-cholestane-3α,7α,12α-triol and 5β-cholestane-3α,7α,12α,25-tetrol were coordinately up-regulated by phenobarbital administration in rats (8) and cholesterol or bile fistula treatment in rabbits (19) . In addition, we have partially purified 5β-cholestane-3α,7α,12α,25-tetrol 24S-hydroxylase in rat liver microsomes by polyethylene glycol precipitation, octylamine agarose chromatography, hydroxylapatite chromatography, and diethylaminoethyl sepharose chromatography. However, the 24S-hydroxylase fraction still contained substantial 5β-cholestane-3α,7α,12α-triol 25-hydroxylase, and 5β-cholestane-3α,7α,12α,25-tetrol 23R-, 24R-, and 27-hydroxylase activities 2 . It was reported that mitochondrial sterol 27-hydroxylase (CYP27) catalyzed not only 27-hydroxylation of cholesterol and 5β-cholestane-3α,7α,12α-triol but also 24-and 25-hydroxylations of cholesterol (35) and 25-hydroxylation of vitamin D (36). Therefore, we speculated that the microsomal 25-hydroxylation of 5β-cholestane-3α,7α,12α-triol and some other hydroxylations of 5β-cholestane-3α,7α,12α,25-tetrol were catalyzed by a common enzyme.
Recently, Furster and Wikvall (18) demonstrated that human microsomal 25-hydroxylation of 5β-cholestane-3α,7α,12α-triol was catalyzed mainly by CYP3A4. This hydroxylation was also catalyzed by recombinant overexpressed human CYP2B6, CYP2C19, and CYP3A5. However, the most abundantly expressed form of P450 in human liver is CYP3A4 (as much as 60% of all hepatic P450) (37), and the rates of 25-hydroxylation by CYP2B6 and CYP2C19 were only 5% and 8% as active as that by CYP3A4, respectively (18) . Recombinant CYP3A5 showed 23% of the activity by Cyp3A4 (18) but hepatic CYP3A5 is polymorphically expressed in only 10 to 30% of humans (38). We did not measure side chain hydroxylase activities by other recombinant expressed human P-450 enzymes, but the following evidence lends support to this hypothesis that not only 25-hydroxylation of 5β-cholestane-3α,7α,12α-triol but also many other microsomal side chain hydroxylations are catalyzed by CYP3A (3A4 and 3A5) in humans. 1) Strong positive correlations existed between testosterone 6β-hydroxylase activity, a marker activity for CYP3A, and the six microsomal side chain hydroxylase activities in human liver microsomes from eight unrelated donors (Table   IV) ; 2) these seven microsomal enzyme activities were markedly suppressed by troleandomycin, a specific inhibitor of CYP3A (39) ( Table V) ; 3) the six microsomal side chain hydroxylase activities were detected in recombinant human CYP3A4 (Fig. 5) ; and 4) the ratio of these six hydroxylase activities in human liver microsomes was similar to that of recombinant CYP3A4 with a strong correlation (r = 0.939). In the IC 50 experiments, troleandomycin markedly inhibited all microsomal hydroxylations we tested, but IC 50 values for human pooled microsomes were somewhat higher than those for recombinant CYP3A4. The difference appears to be caused by the existence of microsomal CYP3A5 which is polymorphically expressed in some human subjects.
Although troleandomycin is a specific inhibitor of CYP3A4 and 3A5, an IC 50 value for CYP3A5 is larger than that for CYP3A4 (39). Actually, the microsomes showed higher IC 50 value than recombinant CYP3A4 when they were determined by assaying testosterone 6β-hydroxylase that is a marker enzyme for CYP3A4 and 3A5.
In mice, CYP3A11 is the major CYP3A enzyme in the liver and it has been reported that the purified CYP3A11, called P450 UT as a trivial name, possesses high activity for testosterone 6β-hydroxylation (40). In addition, the sizes of exons and amino acid sequences of CYP3A11 are highly homologous to those of human CYP3A4 (41). In our experiments, side chain hydroxylations in mouse microsomes were markedly suppressed by troleandomycin (Fig. 6 ) and the IC 50 values were similar to those for human microsomes. Therefore, CYP3A11 seems to be the predominant enzyme responsible for side chain hydroxylations of 5β-cholestane-3α,7α,12α-triol and 5β-cholestane-3α,7α,12α,25-tetrol in mice liver microsomes.
Accumulation of 25-hydroxylated C 27 -bile alcohols is a characteristic feature of CTX.
In the bile and plasma, the major bile alcohol was the glucuronic acid conjugate of 5β-cholestane-3α,7α,12α,25-tetrol, whereas in urine, the glucuronic acid conjugates of 5β-cholestane-3α,7α,12α,23R,25-pentol, 5β-cholestane-3α,7α,12α,24R,25-pentol, and 5β-cholestane-3α,7α,12α,24S,25-pentol predominated (14, 15, 42) . The virtual absence of 5β-cholestane-3α,7α,12α,25-tetrol and the large quantities of pentahydroxy bile alcohols in urine suggested that the urinary pentahydroxy bile alcohols, at least in part, might be formed by the renal hydroxylation of 5β-cholestane-3α,7α,12α,25-tetrol which was produced in the liver (42). In contrast to human liver, CYP3A5 is consistently present while CYP3A4 is expressed in 40 to 90% of subjects in human kidney (43, 44). Thus, CYP3A5 may be the predominant enzyme responsible for the fomation of pentahydroxy bile alcohols in the kidney of CTX patients. It should be mentioned that as reported previously (18), the incubation of human CYP3A4 with 5β-cholestane-3α,7α,12α-triol produced significant amounts of 5β-cholestane-3α,7α,12α,23ξ-tetrol and 5β-cholestane-3α,7α,12α,24ξ-tetrol in addition to a large amount of 5β-cholestane-3α,7α,12α,25-tetrol (Fig. 5A) . Therefore, some of the pentahydroxy bile alcohols produced in CTX may be synthesized by 25-hydroxylation of 5β-cholestane-3α,7α,12α,23ξ-tetrol and 5β-cholestane-3α,7α,12α,24ξ-tetrol.
In Cyp27 -/-mice, hepatic concentrations of early intermediates in bile acid biosynthesis and 25-hydroxylated bile alcohols were significantly elevated compared with those in mice, the pentols except for 5β-cholestane-3α,7α,12α,24S,25-pentol may be eliminated more efficiently from the body than in CTX.
The different response of CYP3A to blocked CYP27 between Cyp27 -/-mice and CTX is intriguing. In this study, we measured CYP3A activities in the single CTX subject, but also previously reported that 5β-cholestane-3α,7α,12α-triol 25-hydroxylase and 5β-cholestane-3α,7α,12α,25-tetrol 24S-hydroxylase activities were not up-regulated in other CTX patients (2, 9). CYP3A4 is responsible for the oxidative metabolism of a wide variety of compounds including an estimated 60% of all clinically used drugs: e.g. dexamethasone, cyclosporin, lovastatin, nifedipine, imidazole antimycotics, and macrolide antibiotics (38), and in addition to 5β-cholestane-3α,7α,12α-triol, 5β-cholestane-3α,7α,12α,25-tetrol and testosterone, several endogenous substrates are also Therefore, it is possible that 5β-cholestane-3α,7α,12α-triol is an efficient inducer of CYP3A expression in mice but not in humans.
In summary, hepatic microsomal 23ξ-, 24ξ-, 25-and 26-hydroxylations of 5β-cholestane-3α,7α,12α-triol and 23R-, 24R-, 24S-and 27-hydroxylations of 5β-cholestane-3α,7α,12α,25-tetrol were all catalyzed by CYP3A. In Cyp27 -/-mice, cholesterol 7α-hydroxylase activity was not up-regulated as much as that in a CTX patient whereas CYP3A was markedly increased. In contrast, considerable up-regulation of cholesterol 7α-hydroxylase without up-regulation of CYP3A was observed in CTX. by guest on October 1, 2017
